Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12609000014257
Ethics application status
Approved
Date submitted
14/11/2008
Date registered
8/01/2009
Date last updated
22/06/2018
Type of registration
Retrospectively registered
Titles & IDs
Public title
Cardiovascular function with switching from Kivexa to Truvada (or from Abacavir to Tenofovir).
Query!
Scientific title
Cardiovascular function with switching from Kivexa to Truvada (or from Abacavir to Tenofovir) in people with Human Immunodeficiency Virus (HIV).
Query!
Secondary ID [1]
282896
0
Nil
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
SKiT
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Human Immunodeficiency Virus (HIV)
3982
0
Query!
Cardiovascular function
3983
0
Query!
Condition category
Condition code
Infection
4180
4180
0
0
Query!
Acquired immune deficiency syndrome (AIDS / HIV)
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
using applanation tonometry to evaluate cardiovascular function in adults with HIV infection switching from ABC-3TC (Kivexa) to TDF-FTC (Truvada) or from ABC (abacavir) to TDF (tenofovir).
Kivexa is a combination HIV pill of Abacavir and lamivudine and Abacavir alone is one of the two drugs in Kivexa. Truvada, another combination pill that contains the drugs tenofovir and emtricitabine and Tenofovir alone is one of the two drugs in Truvada. Truvada and Tenofovir are the two drugs to be used in this study. This is a 24 week study
Truvada dose is 1 x 300mg/200mg tablet, once daily, oral for 24 weeks.
Tenofovir dose is 1 x 300mg tablet, once daily oral for 24 weeks.
Query!
Intervention code [1]
3703
0
Treatment: Drugs
Query!
Comparator / control treatment
N/A
Query!
Control group
Uncontrolled
Query!
Outcomes
Primary outcome [1]
5070
0
To evaluate cardiovascular function measured by radial artery applanation tonometry in HIV-infected adults switching from ABC-3TC to TDF-FTC (or from ABC to TDF).
Query!
Assessment method [1]
5070
0
Query!
Timepoint [1]
5070
0
Baseline and at twenty four weeks
Query!
Secondary outcome [1]
8522
0
To relate these functional arterial changes to HIV-related, metabolic and pro-inflammatory parameters. This will be done by looking at Tonometry reports done at various timepoints throughout the study as well as pathology blood results
Query!
Assessment method [1]
8522
0
Query!
Timepoint [1]
8522
0
twenty four weeks after the start of the study.
The outcome will be assessed also at weeks 4 and 12.
Query!
Eligibility
Key inclusion criteria
provision of written, informed consent.
HIV-infected adults at least 18 years of age.
receiving stable antiretroviral therapy including ABC or ABC-3TC for at least six months.
HIV Ribonucleic Acid (RNA) < 50 copies/ml for at least the previous 3 months.
Framingham risk score = 10%, OR diabetes, OR prior ischaemic cardiovascular disease.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
200
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
Yes
Query!
Key exclusion criteria
clinically significant renal or hepatic disease.
initiation of anti hypertensive therapy in the previous 30 days.
initiation of therapy for dyslipidaemia in the previous 6 weeks.
using corticosteroids, anti-inflammatory drugs or immunomodulating drugs.
contra-indications to TDF or TDF-FTC therapy (e.g. grade 3 renal dysfunction).
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Non-randomised trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Query!
Other design features
Query!
Phase
Phase 4
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Date of first participant enrolment
Anticipated
23/09/2008
Query!
Actual
23/09/2008
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
13/05/2009
Query!
Date of last data collection
Anticipated
Query!
Actual
27/10/2009
Query!
Sample size
Target
20
Query!
Accrual to date
Query!
Final
20
Query!
Recruitment in Australia
Recruitment state(s)
NSW
Query!
Recruitment hospital [1]
11212
0
St Vincent's Hospital (Darlinghurst) - Darlinghurst
Query!
Recruitment postcode(s) [1]
23086
0
2010 - Darlinghurst
Query!
Funding & Sponsors
Funding source category [1]
4171
0
Hospital
Query!
Name [1]
4171
0
St Vincents Hospital
Query!
Address [1]
4171
0
390 Victoria St, Darlinghurst, NSW 2010
Query!
Country [1]
4171
0
Australia
Query!
Primary sponsor type
Hospital
Query!
Name
St Vincents Hospital
Query!
Address
390 Victoria St, Darlinghurst, NSW 2010
Query!
Country
Australia
Query!
Secondary sponsor category [1]
3746
0
None
Query!
Name [1]
3746
0
Query!
Address [1]
3746
0
Query!
Country [1]
3746
0
Query!
Ethics approval
Ethics application status
Approved
Query!
Summary
Brief summary
The purpose is to perform tonometry in HIV-infected adults before and after switching their HIV treatment from Kivexa to Truvada (or from Abacavir to Tenofovir).
Hypothesis: that markers of cardiovascular function (as measured by applanation tonometry) will improve in patients switching from ABC-3TC to TDF-FTC.
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
29133
0
Prof Andrew Carr
Query!
Address
29133
0
St Vincents Hospital
Xavier, Level 4, 390 Victortoria St
Darlinghurst, NSW, 2010
Query!
Country
29133
0
Australia
Query!
Phone
29133
0
+61 2 83823359
Query!
Fax
29133
0
Query!
Email
29133
0
[email protected]
Query!
Contact person for public queries
Name
12290
0
Ms Registered Nurse (RN) Kate Sinn
Query!
Address
12290
0
St Vincents Hospital
Level 4 Xavier Bldg
390 Victoria St, Darlinghurst, NSW 2010
Query!
Country
12290
0
Australia
Query!
Phone
12290
0
+61 2 8382 3060
Query!
Fax
12290
0
Query!
Email
12290
0
[email protected]
Query!
Contact person for scientific queries
Name
3218
0
Prof Professor Andrew Carr
Query!
Address
3218
0
St Vincents Hospital
Level 4 Xavier Bldg
390 Victoria St, Darlinghurst, NSW 2010
Query!
Country
3218
0
Australia
Query!
Phone
3218
0
+61 2 8382 3359
Query!
Fax
3218
0
Query!
Email
3218
0
[email protected]
Query!
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
Source
Title
Year of Publication
DOI
Dimensions AI
Detrimental clinical interaction between ritonavir-boosted protease inhibitors and vinblastine in HIV-infected patients with Hodgkin's lymphoma
2010
https://doi.org/10.1097/qad.0b013e32833db989
Dimensions AI
Lower arterial stiffness and Framingham score after switching abacavir to tenofovir in men at high cardiovascular risk
2010
https://doi.org/10.1097/qad.0b013e32833d568f
Dimensions AI
HIV genetic diversity between plasma and cerebrospinal fluid in patients with HIV encephalitis
2010
https://doi.org/10.1097/qad.0b013e32833e9245
Dimensions AI
HIV-1 Gag evolution in recently infected human leukocyte antigen-B*57 patients with low-level viremia
2010
https://doi.org/10.1097/qad.0b013e32833d8a38
N.B. These documents automatically identified may not have been verified by the study sponsor.
Download to PDF